PCNA-LI, Ki-67 immunostaining, p53 activity and histopathological variables in predicting the clinical outcome in patients with parathyroid carcinoma

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1305-1308

  Lumachi, Franco ^a   Ermani, Mario ^a   Marino, Filippo ^a   Iacobone, Maurizio ^a   Baldessin, Monica ^a   Cappuzzo, Gianluca ^a   Zanella, Simone ^a   Favia, Gennaro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Hyperparathyroidism; Ki 67; p53; Parathyroid cancer; Parathyroid carcinoma; PCNA

Indexed keywords

BIOTIN; CYCLINE; KI 67 ANTIGEN; PEROXIDASE; PROTEIN P53; STREPTAVIDIN; CALCIUM;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; PARATHYROID CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SPINDLE CELL; BLOOD; METABOLISM; MIDDLE AGED; PARATHYROID TUMOR; PATHOLOGY;

ADULT; AGED; CALCIUM; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PARATHYROID NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645813638     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Arnaud CD: The calciotropic hormones and metabolic bone disease. In: Basic and Clinical Endocrinology. Greespan FS and Baxter JD (eds.). East Norwalk, Appleton & Lange, pp. 227-306, 1994.
2. Favia G, Lumachi F, Polistina F and D'Amico DF: Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg 22: 1225-1230, 1998.
3. Shane E: Parathyroid carcinoma. J Clin Endocrinol Metab 86: 485-493, 2001.
4. Lumachi F, Ermani M, Marino F et al: Relationship of AgNOR counts and nuclear DNA content to survival in patients with parathyroid carcinoma. Endocr Relat Cancer 11: 563-569, 2004.
5. Bondeson L, Sandelin K and Grimelius L: Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 17: 820-829, 1993.
6. Horii N, Nishimura Y, Okuno Y et al: Impact of neoadjuvant chemotherapy on Ki-67 and PCNA labeling indices for esophageal squamous cell carcinomas. Intern J Radiat Biol Physiol 49: 527-532, 2001.
7. Nakashima H, Nishida Y, Sugiura H et al: Telomerase, p53 and PCNA in osteosarcoma. Eur J Surg Oncol 29: 564-567, 2003.
8. Lumachi F, Basso S, Zucchetta P et al: Localization of parathyroid tumours 253 in the minimally invasive era: which technique should be chosen? Population-based analysis of patients undergoing parathyroidectomy and factors affecting parathyroid gland detection. Endocr Relat Cancer 8: 63-69, 2000.
9. Lumachi F, Tregnaghi A, Zucchetta P et al: Technetium-99m sestamibi scintigraphy and helical CT together in patients with primary hyperparathyroidism: a prospective clinical study. Br J Radiol 77: 100-103, 2004.
10. Shantz A and Castleman B: Parathyroid carcinoma: a study of 70 cases. Cancer 31: 600-605, 1973.
11. Hundahl SA, Fleming ID, Fremgen AM and Menck HR: Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995. Cancer 86: 538-544, 1999.
12. Sandelin K, Thompson N and Bondeson L: Metastatic parathyroid carcinoma: dilemmas in management. Surgery 110: 878-988, 1992.
13. Shaha AR and Shah JP: Parathyroid carcinoma. A diagnostic and therapeutic challenge. Cancer 86: 378-380, 1999.
14. Obara T, Fujimoto Y, Hirayama A et al: Flow cytometry DNA analysis of parathyroid tumors with special reference to its diagnostic and prognostic value in parathyroid carcinoma. Cancer 65: 1789-1793, 1990.
15. Bocsi J, Perner F, Szucs J et al: DNA content of parathyroid tumors. Anticancer Res 18: 2901-2904, 1998.
16. Erickson LA, Jin L, Papotti M and Lloyd RV: Oxyphil parathyroid carcinomas: a clinicopathologic and immunohistochemical study of 10 cases. Am J Surg Pathol 26: 344-349, 2002.
17. Sinov RV and Haput Y: The cellular response to p53: the decision between life and death. Oncogene 18: 6145-6157, 1999.
18. Lumachi F and Basso S: Apoptosis: life through planned cellular death. Regulating mechanism, control systems, and relations with thyroid diseases. Thyroid 12: 27-34, 2002.
19. Hitt R, Ciruelos E, Amador ML et al: Prognostic value of epidermal growth factor receptor (EGFR) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 41: 453-460, 2005.
20. Naccarato AG, Marcocci C, Miccoli P et al: Bcl-1, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues. J Endocrinol Invest 21: 136-141, 1998.
21. Farnebo F, Auer G, Farnebo LO et al: Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg 23: 68-74, 1999.
22. Cryns VL, Rubio MP, Thor AD et al: p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 78: 1320-1324, 1994.
23. Kameyama K, Takami H, Umemura S et al: PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas. Ann Surg Oncol 7: 301-305, 2000.